This is consistent with the results of our study, in which the overall survival rate of GC patients in the high-PLOD2-expression group was significantly lower than that in the low-PLOD2-expression group, and PLOD2 was the highest-ranked hub gene of the lactylation score model, which was also validated by immunohistochemistry. The gene discussed is PLOD2; the disease is gastric cancer.